Berberine plus lifestyle intervention

DRUG2 trials

Sponsors

China National Center for Cardiovascular Diseases

Conditions

Abdominal ObesityAtherosclerotic Cardiovascular DiseaseDyslipidemiasHypertensionNAFLDObesityObesity, AbdominalPreDiabetes

Phase 4

Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD

CompletedNCT05647915

China National Center for Cardiovascular DiseasesNAFLD, Obesity, Obesity, Abdominal

Start: 2023-07-06End: 2024-08-09Updated: 2025-01-29

Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus

Active, not recruitingNCT05749874

China National Center for Cardiovascular DiseasesAbdominal Obesity, Atherosclerotic Cardiovascular Disease, Dyslipidemias +2

Start: 2023-10-31End: 2026-12-31Updated: 2025-12-31

Related Papers

Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.

2026-01-02